Prevention is safer, faster and cheaper than cure.

Peezy Midstream

Peezy Midstream takes the guesswork out of diagnosis and treatment.

Current urine collection practice means there are 14m failed diagnostic tests in the UK and over 55m in the USA. The need for a gold standard is critical.

Giovanna Forte,
CEO, Forte Medical

Urine is one of the most important carriers of cancer biomarkers, bacteria, protein, glucose and more, all of which can raise the alarm to serious illness. If left undiagnosed these conditions can become far more difficult and costly to treat.

Yet there is no gold standard for urine collection anywhere in the world, leaving patients vulnerable to failed diagnosis and treatment.

  • 47% Gram-negative blood infections are caused by untreated urinary tract infection
  • 59% Obstetric urine tests are contaminated, leading to unreliable pre-natal screening
  • 22% Average rate of unreliability of all urine specimens (USA and UK)

Forte Medical has developed innovative, world-first technology that promotes right-first-time preventative urine-based medicine. Peezy Midstream helps to deliver diagnostic integrity and targeted treatment, which also supports the global fight against Anti Microbial Resistance.

We are now developing The Specimen Collection, a portfolio of devices designed to help with identification of early stage cancers including prostate, testicular, cervical, bladder, kidney and more. Smart digital solutions are planned for each product.

Peezy Midstream is MHRA registered, FDA listed and patented.